RxDoctor Payments Data

Camille Frazier Mills, MD

Cardiovascular Disease · Durham, NCNPI 1346383593

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 77.0% of it on its own, with 5 other manufacturers making up the rest. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$167,093in general payments, 2019–2025

Across 513 payments — averaging $325.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$129K
  • Boston Scientific$21K
  • Lundbeck LLC$8K
  • Biosense Webster, Inc.$6K
  • Abbott$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
$613,716in research payments, 2019–2025

Across 128 payments — averaging $4794.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$593K
  • Boston Scientific$21K

What the payments were for

  • Consulting fees$30,81918%
  • Speaking & faculty fees$96,93158%
  • Travel & lodging$26,44716%
  • Food & beverage$12,7678%
  • Education$1300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)328$128,636
Boston Scientific149$20,875
Lundbeck LLC7$7,813
Biosense Webster, Inc.9$6,458
Abbott19$3,211
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$100

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$167,093 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$174,758
Medicare patients
1,339
Services billed
3,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban165$155,270
XareltoRivaroxaban25$19,513
MultaqDronedarone Hcl23$18,856
Amiodarone Hcl66$1,830
Midodrine Hcl27$1,782
Metoprolol Succinate89$1,681
Pyridostigmine Bromide14$793
Nebivolol Hcl20$699
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$339
Potassium Chloride13$303
Losartan Potassium18$223
Metoprolol Tartrate17$82
Furosemide25$59
Spironolactone12$43
Carvedilol11$37

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →